Eurobio Scientific Société anonyme (EPA:ALERS)
France
· Delayed Price · Currency is EUR 25.00
-0.45 (-1.77%)
May 29, 2025, 4:29 PM CET
EPA:ALERS Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Other Revenue | -0 | - | - | - | - | Upgrade
|
| Revenue | 154.95 | 130.65 | 152.9 | 185.32 | 189.19 | Upgrade
|
| Revenue Growth (YoY) | 18.60% | -14.56% | -17.50% | -2.04% | 218.10% | Upgrade
|
| Cost of Revenue | 82.99 | 73.16 | 81.66 | 85.91 | 80.68 | Upgrade
|
| Gross Profit | 71.95 | 57.49 | 71.24 | 99.41 | 108.51 | Upgrade
|
| Selling, General & Admin | 38.86 | 33.52 | 31 | 24.5 | 22.5 | Upgrade
|
| Research & Development | 4.65 | 5.91 | 3.47 | - | - | Upgrade
|
| Operating Expenses | 52.02 | 47.35 | 40.37 | 29.29 | 27.3 | Upgrade
|
| Operating Income | 19.93 | 10.14 | 30.87 | 70.12 | 81.21 | Upgrade
|
| Interest Expense | -4.13 | -4.36 | -1.26 | -0.41 | -0.6 | Upgrade
|
| Interest & Investment Income | 1.48 | 1.12 | 0.04 | - | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.69 | 0.75 | 0.67 | 0.36 | -0.19 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.71 | 0.77 | 0.04 | -0.05 | 0.44 | Upgrade
|
| EBT Excluding Unusual Items | 14.26 | 8.42 | 30.35 | 70.01 | 80.86 | Upgrade
|
| Merger & Restructuring Charges | -6.6 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 0.23 | - | Upgrade
|
| Other Unusual Items | -1.38 | -1.45 | -0.67 | 1.08 | 0.03 | Upgrade
|
| Pretax Income | 6.28 | 6.98 | 29.68 | 71.31 | 80.89 | Upgrade
|
| Income Tax Expense | 2.29 | 2.14 | 4.75 | 10.77 | 7.41 | Upgrade
|
| Earnings From Continuing Operations | 4 | 4.84 | 24.94 | 60.54 | 73.48 | Upgrade
|
| Net Income | 4 | 4.84 | 24.94 | 60.54 | 73.48 | Upgrade
|
| Net Income to Common | 4 | 4.84 | 24.94 | 60.54 | 73.48 | Upgrade
|
| Net Income Growth | -17.31% | -80.61% | -58.81% | -17.61% | 2230.51% | Upgrade
|
| Shares Outstanding (Basic) | 10 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | -8.49% | -1.40% | 4.59% | -3.35% | 0.10% | Upgrade
|
| EPS (Basic) | 0.39 | 0.43 | 2.20 | 5.58 | 6.56 | Upgrade
|
| EPS (Diluted) | 0.39 | 0.43 | 2.20 | 5.57 | 6.53 | Upgrade
|
| EPS Growth | -9.42% | -80.44% | -60.53% | -14.70% | 2232.14% | Upgrade
|
| Free Cash Flow | 13.45 | 22.71 | 40.24 | 64.07 | 52.63 | Upgrade
|
| Free Cash Flow Per Share | 1.31 | 2.02 | 3.54 | 5.89 | 4.68 | Upgrade
|
| Gross Margin | 46.44% | 44.00% | 46.59% | 53.64% | 57.35% | Upgrade
|
| Operating Margin | 12.86% | 7.76% | 20.19% | 37.84% | 42.93% | Upgrade
|
| Profit Margin | 2.58% | 3.70% | 16.31% | 32.67% | 38.84% | Upgrade
|
| Free Cash Flow Margin | 8.68% | 17.39% | 26.32% | 34.57% | 27.82% | Upgrade
|
| EBITDA | 29.45 | 23.29 | 40.5 | 77.98 | 88.22 | Upgrade
|
| EBITDA Margin | 19.00% | 17.82% | 26.49% | 42.08% | 46.63% | Upgrade
|
| D&A For EBITDA | 9.51 | 13.15 | 9.63 | 7.87 | 7.01 | Upgrade
|
| EBIT | 19.93 | 10.14 | 30.87 | 70.12 | 81.21 | Upgrade
|
| EBIT Margin | 12.86% | 7.76% | 20.19% | 37.84% | 42.93% | Upgrade
|
| Effective Tax Rate | 36.38% | 30.70% | 15.99% | 15.10% | 9.16% | Upgrade
|
| Revenue as Reported | 154.95 | 130.65 | 152.9 | 185.32 | 189.19 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.